{"id":43209,"date":"2026-03-27T04:22:54","date_gmt":"2026-03-27T08:22:54","guid":{"rendered":"https:\/\/tvdelmarva.com\/wp\/new-copd-treatment-shows-promise-in-reducing-breathing-complications\/"},"modified":"2026-03-27T04:22:54","modified_gmt":"2026-03-27T08:22:54","slug":"new-copd-treatment-shows-promise-in-reducing-breathing-complications","status":"publish","type":"post","link":"https:\/\/tvdelmarva.com\/wp\/new-copd-treatment-shows-promise-in-reducing-breathing-complications\/","title":{"rendered":"New COPD Treatment Shows Promise in Reducing Breathing Complications"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n

AstraZeneca announced Friday that their investigational breathing medication demonstrated significant success in decreasing severe episodes for patients suffering from chronic obstructive pulmonary disease during two major advanced clinical trials.<\/p>

The pharmaceutical company reported that tozorakimab achieved its primary objective in both studies, successfully lowering the yearly occurrence of moderate-to-severe COPD episodes compared to inactive treatment in the main study group of previous smokers and across all participants.<\/p>

Both current and past tobacco users with different degrees of respiratory damage and varying white blood cell levels participated in the research, according to the company.<\/p>

COPD represents a long-term medical condition that limits air passage and creates difficulty breathing. Although cigarette smoking serves as the primary cause, exposure to vapors, industrial chemicals, and workplace particles can also trigger the disease’s development.<\/p>

The experimental medication falls under the monoclonal antibody treatment category, functioning by mimicking natural immune responses and blocking interleukin-33, a protein that contributes to inflammatory processes.<\/p>

According to AstraZeneca, their medication could potentially decrease inflammation and break the harmful pattern of mucus problems that may intensify COPD symptoms in patients. The World Health Organization ranks this respiratory disease as the fourth most common cause of death globally.<\/p>

The pharmaceutical company plans to share comprehensive results from both clinical trials at a future medical conference.<\/p>

This development follows AstraZeneca’s September announcement that their asthma medication Fasenra did not successfully decrease symptom worsening in COPD patients during a different advanced study.<\/p>","protected":false},"excerpt":{"rendered":"

Pharmaceutical company AstraZeneca announced Friday that their experimental respiratory medication successfully reduced severe breathing episodes in COPD patients during advanced clinical trials. The drug, called tozorakimab, targets inflammation that worsens the chronic lung condition affecting millions worldwide.<\/p>\n","protected":false},"author":4,"featured_media":43208,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[837],"tags":[],"class_list":["post-43209","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/03\/news-1774599773900.jpg?fit=450%2C300&ssl=1","jetpack_shortlink":"https:\/\/wp.me\/pbtNqq-beV","jetpack-related-posts":[{"id":54712,"url":"https:\/\/tvdelmarva.com\/wp\/new-drug-shows-promise-in-reducing-chronic-lung-disease-flare-ups\/","url_meta":{"origin":43209,"position":0},"title":"New Drug Shows Promise in Reducing Chronic Lung Disease Flare-ups","author":"Admin","date":"April 20, 2026","format":false,"excerpt":"Pharmaceutical company AstraZeneca announced Monday that their experimental drug tozorakimab successfully reduced flare-ups of chronic obstructive pulmonary disease in a major clinical trial. The treatment showed significant benefits for both current and former smokers who continued experiencing severe symptoms despite standard care.","rel":"","context":"In "Health"","block_context":{"text":"Health","link":"https:\/\/tvdelmarva.com\/wp\/category\/health\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/04\/news-1776669732050.jpg?fit=450%2C302&ssl=1&resize=350%2C200","width":350,"height":200},"classes":[]},{"id":43369,"url":"https:\/\/tvdelmarva.com\/wp\/eli-lillys-eczema-treatment-shows-lasting-relief-in-four-year-study\/","url_meta":{"origin":43209,"position":1},"title":"Eli Lilly’s Eczema Treatment Shows Lasting Relief in Four-Year Study","author":"Admin","date":"March 27, 2026","format":false,"excerpt":"Pharmaceutical giant Eli Lilly announced that their eczema medication Ebglyss demonstrated sustained effectiveness over four years in treating severe skin conditions. The monthly injection provided significant itch relief and skin clearance for patients with moderate-to-severe atopic dermatitis.","rel":"","context":"In "Health"","block_context":{"text":"Health","link":"https:\/\/tvdelmarva.com\/wp\/category\/health\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/03\/news-1774621492281.jpg?fit=450%2C300&ssl=1&resize=350%2C200","width":350,"height":200},"classes":[]},{"id":21412,"url":"https:\/\/tvdelmarva.com\/wp\/experimental-psychedelic-treatment-shows-promise-for-severe-depression\/","url_meta":{"origin":43209,"position":2},"title":"Experimental Psychedelic Treatment Shows Promise for Severe Depression","author":"Admin","date":"February 17, 2026","format":false,"excerpt":"A pharmaceutical company reported successful results from a major clinical trial testing a psilocybin-based therapy for patients with severe depression. The treatment showed significant improvement in reducing depression symptoms compared to lower doses in a study of over 1,000 participants.","rel":"","context":"In "Health"","block_context":{"text":"Health","link":"https:\/\/tvdelmarva.com\/wp\/category\/health\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/02\/news-1771330736908.png?fit=1200%2C675&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/02\/news-1771330736908.png?fit=1200%2C675&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/02\/news-1771330736908.png?fit=1200%2C675&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/02\/news-1771330736908.png?fit=1200%2C675&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/02\/news-1771330736908.png?fit=1200%2C675&ssl=1&resize=1050%2C600 3x"},"classes":[]},{"id":30982,"url":"https:\/\/tvdelmarva.com\/wp\/japanese-drugmaker-halts-skin-treatment-trials-over-cancer-concerns\/","url_meta":{"origin":43209,"position":3},"title":"Japanese Drugmaker Halts Skin Treatment Trials Over Cancer Concerns","author":"Admin","date":"March 3, 2026","format":false,"excerpt":"Pharmaceutical company Kyowa Kirin has terminated all clinical trials for an experimental skin condition medication after safety reviews revealed potential cancer risks. The drug was being tested to treat severe eczema and other inflammatory skin disorders.","rel":"","context":"In "Health"","block_context":{"text":"Health","link":"https:\/\/tvdelmarva.com\/wp\/category\/health\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/03\/news-1772547661813.png?fit=1200%2C675&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/03\/news-1772547661813.png?fit=1200%2C675&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/03\/news-1772547661813.png?fit=1200%2C675&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/03\/news-1772547661813.png?fit=1200%2C675&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/03\/news-1772547661813.png?fit=1200%2C675&ssl=1&resize=1050%2C600 3x"},"classes":[]},{"id":61625,"url":"https:\/\/tvdelmarva.com\/wp\/pharmaceutical-company-reports-success-in-trial-for-rare-liver-disease-treatment\/","url_meta":{"origin":43209,"position":4},"title":"Pharmaceutical Company Reports Success in Trial for Rare Liver Disease Treatment","author":"Admin","date":"May 4, 2026","format":false,"excerpt":"Mirum Pharmaceuticals announced positive results from a clinical trial testing an experimental medication for severe itching in patients with a rare liver condition. The drug, volixibat, showed statistically significant improvement compared to placebo in reducing symptoms for patients with primary sclerosing cholangitis.","rel":"","context":"In "Health"","block_context":{"text":"Health","link":"https:\/\/tvdelmarva.com\/wp\/category\/health\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/05\/news-1777919815646.png?fit=1200%2C675&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/05\/news-1777919815646.png?fit=1200%2C675&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/05\/news-1777919815646.png?fit=1200%2C675&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/05\/news-1777919815646.png?fit=1200%2C675&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/05\/news-1777919815646.png?fit=1200%2C675&ssl=1&resize=1050%2C600 3x"},"classes":[]},{"id":21821,"url":"https:\/\/tvdelmarva.com\/wp\/australian-biotech-firm-secures-rights-to-promising-heart-drug-for-kidney-patients\/","url_meta":{"origin":43209,"position":5},"title":"Australian Biotech Firm Secures Rights to Promising Heart Drug for Kidney Patients","author":"Admin","date":"February 17, 2026","format":false,"excerpt":"Australian pharmaceutical company CSL has secured exclusive rights to develop and market a new antibody treatment designed to reduce heart complications in patients with advanced kidney disease. The $100 million upfront deal with Eli Lilly could lead to significant treatment advances for patients facing both kidney failure and cardiovascular risks.","rel":"","context":"In "Health"","block_context":{"text":"Health","link":"https:\/\/tvdelmarva.com\/wp\/category\/health\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/02\/news-1771366690140.jpg?fit=450%2C300&ssl=1&resize=350%2C200","width":350,"height":200},"classes":[]}],"jetpack_sharing_enabled":true,"jetpack_likes_enabled":true,"_links":{"self":[{"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/posts\/43209","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/comments?post=43209"}],"version-history":[{"count":0,"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/posts\/43209\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/media\/43208"}],"wp:attachment":[{"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/media?parent=43209"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/categories?post=43209"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/tags?post=43209"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}